Albany Molecular Research Revenue Quarterly YoY Growth:
44.26% for Dec. 31, 2012Albany Molecular Research Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 44.26% |
| Sept. 30, 2012 | 11.03% |
| June 30, 2012 | -7.18% |
| March 31, 2012 | -5.71% |
| Dec. 31, 2011 | -4.22% |
| Sept. 30, 2011 | -0.77% |
| June 30, 2011 | 8.90% |
| March 31, 2011 | 15.44% |
| Dec. 31, 2010 | 12.04% |
| Sept. 30, 2010 | 6.19% |
| June 30, 2010 | -3.57% |
| March 31, 2010 | -8.70% |
| Dec. 31, 2009 | -23.01% |
| Sept. 30, 2009 | -22.32% |
| June 30, 2009 | -11.44% |
| March 31, 2009 | 0.86% |
| Dec. 31, 2008 | 19.41% |
| Sept. 30, 2008 | 29.03% |
| June 30, 2008 | 17.39% |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
| Sept. 30, 2000 | Go Pro |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
AMRI Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Cambrex Corporation | 6.63% |
| Achillion Pharmaceuticals | -100.0% |
| Anacor Pharmaceuticals | 26.66% |
AMRI Revenue Quarterly YoY Growth Rankings
| Overall |
94th percentile 426 of 8007 |
| Sector |
87th percentile 86 of 685 in Healthcare |
| Industry |
84th percentile 39 of 248 in Biotechnology |
AMRI Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -23.01% | Dec 2009 |
| Maximum | 44.26% | Dec 2012 |
| Average | 4.09% |
